We are happy to announce our strategic partnership with BioAgilytix on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, Bioasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic. To learn more, please visit:

https://www.bioasis.us/bioasis-and-bioagilytix-announce-strategic-collaboration-to-advance-xb3-tm-001-bioasis-lead-investigational-candidate-to-treat-her2-brain-cancer-to-ind-submission-and-into-the-clinic/